Drugs / LTG-001
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07341152 | Oct → Nov 2025 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06049095 | Oct 2023 → Sep 2026 expected | — | Latigo Biotherapeutics | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07102459 | Jul 2025 → Jan 2026 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT06774625 | Dec 2024 → Aug 2025 | — | Latigo Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06774625 ↗ |
| Route | Intravenous | “orally or intravenously administered LTG-001” NCT06049095 ↗ |
| Route | Oral | “orally or intravenously administered LTG-001” NCT06049095 ↗ |